|
Description Digestive system disease is one of frequently-occurring diseases. According to statistics of WHO, there are at least 250 million digestive tract patients, mainly suffering from canker.
Inhibition of gastric acid secretion is the key treatment method for peptic ulcer, duodenal ulcer and gastroesophageal reflux disease. The H+ / K+ ATP enzyme in gastric parietal cells can reduce gastric acid secretion. By inhibiting the functioning of this transporter, the drug prevents formation of gastric acid. Proton pump inhibitor, namely H+/K+-ATP enzyme, inhibits the avidity of H+/K+-ATP enzyme to block gastric acid secretion caused by any stimulation Esomeprazole is a proton pump inhibitor that appeared on the market in 2000. It becomes popular in the market because of high bioavailability, effective and lasting inhibition of gastric acid and low toxic and side effect. Total sales revenue of Nexium (trade name of esomeprazole produced by Astra Zeneca) since it was launched is over tens of billions dollars, making it one of the most important products from Astra Zeneca. Patent No. 94190335. 4 is the most crucial patent for Nexium which expires in May 2014. To avoid time-consuming and costly patent infringement lawsuits, Astra Zeneca announced in October 2011 that generic drug manufacturers with cooperation intention needed to pay royalty before producing esomeprazole generic drugs. Though generic drugs take part of Nexium's market, Astra Zeneca can recoup the loss by charging patent royalty. Statistics shows that there are over 120 million people suffering from enterogastric diseases in China, which is the most in the world. Incidence of peptic ulcer is 10% while that of chronic gastritis is 30%. Nexium produced by Astra Zeneca entered China in 2004. According to CRI's investigation in China market, the CAGR of sales revenue of esomeprazole outstepped 48% from 2005 to 2014. In 2014, the sales value in sample hospital exceeded CNY 80 million, which was spectacularly successful. By the end of 2014, Chinese market was absolutely dominated by products from Astra Zeneca. Chongqing LUMMY Pharmaceutical Co., Ltd. applied for 4 new drug registrations with esomeprazole in 2010, which was approved in August 2013. It is estimated that market pattern of esomeprazole in China will change in 2015. In the short term Nexium produced by Astra Zeneca will still have an absolute advantage in the market, but its market share will decline in the long run. Through this report, the readers can acquire the following information:
-Sales Price of Esomeprazole (Nexium) in China Hospital Market
-Major Esomeprazole Manufacturers in China
Patent Status of Esomeprazole in China
-Share of Esomeprazole in Different Dosage Forms in China Hospital Market
-Prospect of China Esomeprazole Market The Following Enterprises and People Are Recommended to Purchase This Report:
-Manufacturers of Digestive System Diseases Medication
-Investors on China Digestive System Diseases Drug Market
|
Login
Location : 
